Stay updated with breaking news from Earth Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced upcoming presentations by its collaborators
− Agreement with Sinotau Pharmaceutical Group part of Company’s global strategy to increase clinician and patient access to innovative diagnostic imaging agent –OXFORD, England & MONROE TOWNSHIP, N.J.--(BUSINESS WIRE)--Blue Earth Diagnostics Ltd, a Bracco company and recognised leader in the development and commerci...
− Post-hoc analysis from Blue Earth Diagnostics’ Phase 3 SPOTLIGHT trial provides data about treatment planning, particularly when curative salvage therapy is considered –For U.S audiences onlyMONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in...
Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.
POSLUMA is now commercially available in multiple U.S. radiopharmacies, with nationwide availability by end of June 2023